These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 38255995)

  • 1. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy.
    Carrera-Aguado I; Marcos-Zazo L; Carrancio-Salán P; Guerra-Paes E; Sánchez-Juanes F; Muñoz-Félix JM
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor vessel co-option: The past & the future.
    Cuypers A; Truong AK; Becker LM; Saavedra-García P; Carmeliet P
    Front Oncol; 2022; 12():965277. PubMed ID: 36119528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
    Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
    Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
    Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
    Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
    Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
    Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.
    Shao Y; Lu B
    Cancer Metastasis Rev; 2022 Mar; 41(1):173-191. PubMed ID: 34664157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
    Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
    Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological features of vessel co-option versus sprouting angiogenesis.
    Latacz E; Caspani E; Barnhill R; Lugassy C; Verhoef C; Grünhagen D; Van Laere S; Fernández Moro C; Gerling M; Dirix M; Dirix LY; Vermeulen PB
    Angiogenesis; 2020 Feb; 23(1):43-54. PubMed ID: 31655928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
    Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
    Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells.
    Cuypers A; Teuwen LA; Bridgeman VL; de Rooij LPMH; Eelen G; Dewerchin M; Cantelmo AR; Kalucka J; Bouché A; Vinckier S; Carton A; Manderveld A; Vermeulen PB; Reynolds AR; Carmeliet P
    STAR Protoc; 2022 Dec; 3(4):101691. PubMed ID: 36173713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vessel co-option: a unique vascular-immune niche in liver cancer.
    Yang D; Dang S; Wang Z; Xie M; Li X; Ding X
    Front Oncol; 2024; 14():1386772. PubMed ID: 38737903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vessel co-option in glioblastoma: emerging insights and opportunities.
    Seano G; Jain RK
    Angiogenesis; 2020 Feb; 23(1):9-16. PubMed ID: 31679081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.
    Lazaris A; Amri A; Petrillo SK; Zoroquiain P; Ibrahim N; Salman A; Gao ZH; Vermeulen PB; Metrakos P
    J Pathol Clin Res; 2018 Jul; 4(3):184-192. PubMed ID: 29654716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad targeting of angiogenesis for cancer prevention and therapy.
    Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
    Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
    Olejarz W; Kubiak-Tomaszewska G; Chrzanowska A; Lorenc T
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vessel co-option in cancer.
    Kuczynski EA; Vermeulen PB; Pezzella F; Kerbel RS; Reynolds AR
    Nat Rev Clin Oncol; 2019 Aug; 16(8):469-493. PubMed ID: 30816337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.
    Leenders WP; Küsters B; de Waal RM
    Endothelium; 2002; 9(2):83-7. PubMed ID: 12200959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.